Read More

96% Of S&P 500 Stocks Show Upside Potential Vs. Street Estimates: Which Offers The Best Opportunity?

480 out of 500 S&P 500 companies are trading below analysts' price targets, indicating potential profit opportunities. April has been bleak for the market, but some undervalued stocks may be worth buying. Top 5 stocks with biggest gap between price and target: CCL, BIO, WBD, CZR, CCO.

BIO

Read More

AbbVie Announces Phase 3 SELECT-GCA Study Of Upadacitinib Results In Patients With Giant Cell Arteritis; In Combination With A 26-week Steroid Taper Regimen Achieved Its Primary Endpoint Of Sustained Remission; Key Secondary Endpoints Were Also Met

−     Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg) with a 26-week steroid taper

ABBV

Read More

Actinium Highlights Ability Of Iomab-B To Overcome High-Risk TP53 Mutation Resulting In Improvement In Overall Survival In Patients With Active Relapsed Refractory AML At The European Bone Marrow Transplant Annual Meeting

-- Iomab-B led bone marrow transplant produced high rates of complete remission and durable complete remission regardless of TP53 mutation status in patients age 55 and above with high-risk active relapsed or

ATNM